What triggered Novo Nordisk shares' latest price surge

Traders Union
All News
Financial News
Novo Nordisk rises 2.10% today

Highlights

Novo Nordisk advanced its DKK 15 billion share buyback and announced international oral Wegovy launches after strong financial results.
The company unveiled next-generation diabetes clinical data and updated its Rybelsus tablet in Canada, while approving major dividends and board changes.
Technicals show Novo Nordisk trades below major averages with mixed momentum signals, projecting a sideways $40.82 to $42.74 range short term.

Buyback escalation and new drug data reshape investor focus

Novo Nordisk has advanced its share buyback program with a framework of up to DKK 15 billion, and its treasury stake has reached 0.8%. The company also recently presented new clinical findings for next-generation diabetes therapies at the American Diabetes Association conference, with additional attention to preparations for international launches of the oral Wegovy tablet, including in the United Arab Emirates. Other recent developments include an updated Rybelsus tablet formulation launch in Canada, major dividend approvals, and changes to the board after strong financial results.

Anton Kharitonov, expert at Traders Union, points out that Novo Nordisk's stock remains under persistent selling pressure below key moving averages. He highlights the lack of directional momentum, with most technical indicators suggesting oversold conditions despite today’s minor bounce. Kharitonov notes that the buyback news and next-generation therapy headlines have not shifted bearish sentiment or reversed the technical downtrend. He doubts the effectiveness of recent management and board changes, given price action and the lack of strong buying signals. "Until the $42.74 mark is cleared with conviction, I remain cautious and expect sellers to dominate further," he says.

Viktoras Karapetjanc, expert at Traders Union, sees ongoing share buybacks and research presentations as a strong foundation for Novo Nordisk’s future momentum. He views the oral Wegovy rollout as a catalyst that can re-energize demand globally. Karapetjanc believes robust dividend policies and upcoming product launches signal confidence from management. "The bullish structure remains intact, and I expect further growth once short-term headwinds subside," he states.

Oversold signals persist amid resistance and weak directional momentum

Momentum signals are mixed: the MACD and Average Directional Index (ADX) on the daily chart both provide neutral readings, suggesting a lack of clear directional momentum. The Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) highlight oversold conditions, while Bull/Bear Power (BBP) is negative at -1.36, indicating sellers dominate intraday trading and reinforcing an oversold tone. Intraday volatility stands at 1.87% and price action shows firm intraday strength toward the highs. The nearest dynamic resistance is at the Ichimoku Kijun level of $44.40, while the 50-day moving average offers initial support. There is a noticeable divergence between short-term oversold signals and the day’s upward momentum.

Previously it was reported that Novo Nordisk’s stock remained under technical pressure despite ongoing share buybacks and promising advances in its drug pipeline. The latest mixed momentum signals and persistent oversold conditions confirm a generally cautious outlook, with traders advised to focus on $42.74 as the critical threshold for any potential bullish reversal in the near term.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.